Connor Clark & Lunn Investment Management Ltd. Takes $5.86 Million Position in Harrow, Inc. (NASDAQ:HROW)

Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 130,424 shares of the company's stock, valued at approximately $5,864,000. Connor Clark & Lunn Investment Management Ltd. owned about 0.37% of Harrow as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the company. First Turn Management LLC acquired a new position in Harrow in the third quarter valued at $14,683,000. Quest Partners LLC purchased a new position in shares of Harrow in the 3rd quarter worth about $29,000. Huntington National Bank acquired a new position in shares of Harrow in the 3rd quarter valued at about $164,000. Oppenheimer & Co. Inc. purchased a new stake in shares of Harrow during the 3rd quarter worth about $1,267,000. Finally, Corrado Advisors LLC purchased a new stake in shares of Harrow during the 3rd quarter worth about $331,000. Institutional investors and hedge funds own 72.76% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on HROW shares. B. Riley restated a "buy" rating and set a $50.00 target price on shares of Harrow in a report on Thursday, August 29th. Lake Street Capital raised their price objective on Harrow from $45.00 to $55.00 and gave the company a "buy" rating in a research report on Friday, October 4th. Finally, Craig Hallum upped their target price on Harrow from $45.00 to $65.00 and gave the stock a "buy" rating in a research report on Friday, October 4th.

Harrow Stock Down 2.2 %

Shares of HROW traded down $0.98 during midday trading on Friday, hitting $42.90. The company had a trading volume of 330,682 shares, compared to its average volume of 718,634. The stock has a market cap of $1.53 billion, a price-to-earnings ratio of -45.64 and a beta of 0.76. The company's 50 day moving average price is $47.88 and its 200 day moving average price is $33.35. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. Harrow, Inc. has a 52 week low of $8.72 and a 52 week high of $59.23.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.